Phaseline

Companies › Ambros Therapeutics

Ambros Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Neurology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AMBTX-01 (Neridronate)
Bisphosphonate
–Phase 3Complex Regional Pain Syndrome Type IDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07210515AMBTX-01 (Neridronate)Phase 3Complex Regional Pain Syndrome Type INeurologyDec 2027
NCT07857733AMBTX-01 (Neridronate)Phase 3Complex Regional Pain Syndrome Type INeurologyDec 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Prilenia Cerevance Green Valley (Shanghai) Pharmaceuticals CereMark Pharma MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.